Hypoactive Sexual Desire Disorder(HSDD) Clinical Trial
Official title:
Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP101 After Multiple Doses Administration in Healthy Volunteers
| Verified date | February 2020 |
| Source | Ivix LLX |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers.
| Status | Completed |
| Enrollment | 18 |
| Est. completion date | September 19, 2017 |
| Est. primary completion date | June 21, 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years to 40 Years |
| Eligibility |
Inclusion Criteria: - Healthy women aged from 18 to 40, inclusive. - Verified diagnosis "healthy": absence gastrointestinal, hepatic, renal, cardiovascular, endocrine, central nervous system, ear, nose, throat (ENT) and gynecological disorders (performed standard clinical, laboratory and instrumental assessments did not reveal any disorders). - Body mass index (BMI) within range from 18.5 to 30 kg/m^2. - Subject consent not to intake alcohol during the entire study period; negative alcohol breath test at screening and before start of Investigational Product administration. - Negative pregnancy test result at screening and before start of Investigational Product administration. - Consent to use adequate methods of contraception throughout the study. - Normal regular menstrual cycle of 28 +/- 7 days duration for at least 6 months before study enrollment. - Women with stable sexual partner. Exclusion Criteria: - Chronic cardiovascular, respiratory, neuroendocrine, genitourinary systems disorders, as well as gastrointestinal, hepatic, renal, blood, and ENT disorders (including acute and chronic rhinitis, sinusitis, and others). - Gynecological disorders (polycystic ovary syndrome, mommas, endometriosis, inflammatory diseases and others). - Positive cervical cytology Papanicolaou (PAP) test in medical anamnesis within 12 months before screening. - Lab abnormalities (blood hematology and biochemistry and urinalysis) at screening. - Electrocardiogram (ECG) abnormalities at screening, and before start of Investigational Product administration. - Systolic blood pressure in a sitting position below 100 mm Hg or above 140 mm Hg; and/or diastolic pressure below 60 mm Hg or above 90 mm Hg at screening and before start of Investigational Product administration. - Heart rate less than 60 beats/min or more than 90 beats/min at screening, and before start of Investigational Product administration. - Signs of malignant neoplasms in medical history, during the examination at any time prior to start of Investigational Product administration. - Psychiatric disorders (including any form of schizophrenia, epilepsy, bipolar affective disorder and others), intake of psychotropic agents. - Chronic pain syndromes (including chronic pelvic pain syndrome). - Acute infections within 4 weeks before screening. - Regular intake of medications (including nonprescription drugs, vitamins, and Supplements) within 2 weeks before screening. - Intake of more than 5 units of alcohol per week (1 unit of alcohol is equivalent to 0.5 liter of beer, 200 ml wine or 30 ml of spirit (pure alcohol)) or historical information about alcoholism, substance abuse, prescription drug abuse. - Smoking more than 10 cigarettes a day. - Pregnancy or breastfeeding, positive urine pregnancy at screening and before the start of Investigational Product administration. |
| Country | Name | City | State |
|---|---|---|---|
| Russian Federation | Research center Eco-Safety LLC | Saint Petersburg |
| Lead Sponsor | Collaborator |
|---|---|
| Ivix LLX |
Russian Federation,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incidence of treatment-emergent Adverse Events | To evaluate frequency, seriousness, and severity of adverse events, including events of dose-limiting toxicity in healthy volunteers receiving different doses of BP101 compared to placebo after multiple administrations. | 6 weeks | |
| Secondary | BP101 maximum plasma concentration (Cmax) | To determine pharmacokinetic parameter of maximum plasma concentration (Cmax) after single administration of BP101 in healthy volunteers. | Day 1 | |
| Secondary | BP101 area under the concentration versus time curve (AUC) | To determine pharmacokinetic parameter area under the plasma concentration versus time curve (AUC) after single administration of BP101 in healthy volunteers. | Day 1 | |
| Secondary | BP101 time to maximum plasma concentration (Tmax) | To determine pharmacokinetic parameter time to maximum plasma concentration (Tmax) after single administration of BP101 in healthy volunteers. | Day 1 | |
| Secondary | BP101 half-life time (T1/2) | To determine pharmacokinetic parameter of plasma half-life time (T1/2) after single administration of BP101 in healthy volunteers. | Day 1 | |
| Secondary | Change from Baseline in Female Sexual Function Index score | To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function Index (FSFI). | 2 weeks | |
| Secondary | Change from Baseline in Female Sexual Function Index score | To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function Index (FSFI). | 6 weeks | |
| Secondary | Change from Baseline in Female Sexual Distress Scale-Revised score | To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Distress Scale-Revised (FSDS-R). | 2 weeks | |
| Secondary | Change from Baseline in Female Sexual Distress Scale-Revised score | To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Distress Scale-Revised (FSDS-R). | 6 weeks | |
| Secondary | Change from Baseline in Female Sexual Function questionnaire score | To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function (FSF) questionnaire. | 2 weeks | |
| Secondary | Change from Baseline in Female Sexual Function questionnaire score | To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Female Sexual Function (FSF) questionnaire. | 6 weeks | |
| Secondary | Change from Baseline in Arizona Sexual Experience Scale score | To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Arizona Sexual Experience Scale (ASEX) questionnaire. | 2 weeks | |
| Secondary | Change from Baseline in Arizona Sexual Experience Scale score | To evaluate impact of BP101 in comparison with placebo on sexual function in healthy volunteers using Arizona Sexual Experience Scale (ASEX) questionnaire. | 6 weeks |